World Advanced Therapeutics Summit on November 10-12, 2026 in Incheon, Republic of Korea

South Korea is fast becoming the epicentre of targeted therapeutics innovation. To meet the growing demand for safer, more effective drugs with broader therapeutic windows that can improve on standard of care treatments and meet an unmet medical need, the World Advanced Therapeutics Summit South Korea brings together two of the hottest modalities under one roof to create unparalleled opportunities for idea exchange, collaboration, and networking.

Taking place as two co-located events with the flagship 2nd World RNA-Based Therapeutics and Vaccines Summit South Korea and the brand-new World Cell and Gene Therapy Summit South Korea, this is the opportunity to gain comprehensive coverage of the fastest-growing R and D areas in Korea.

With an audience ranging from C-level execs and VP/Directors, the summit joins together over 160 leading experts to drive innovation, differentiate your pipeline and accelerate drug development.

URLs:

Website: https://go.evvnt.com/3703543-0?pid=10008

Tickets: https://go.evvnt.com/3703543-2?pid=10008

Brochure: https://go.evvnt.com/3703543-3?pid=10008

Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 2199.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 1999.00,

Drug Developer Pricing - Conference Only: USD 1799.00,

Academic Pricing - Conference + 2 Workshops: USD 1899.00,

Academic Pricing - Conference + 1 Workshop: USD 1749.00,

Academic Pricing - Conference Only: USD 1599.00,

Service Provider Pricing - Conference + 2 Workshops: USD 5149.00,

Service Provider Pricing - Conference + 1 Workshop: USD 4499.00,

Service Provider Pricing - Conference Only: USD 3849.00

Speakers: Gena Lee Meyers, Business Development Lead, Curocell, Peggy Sotiropoulou, Chief Scientific Officer, T-Knife Therapeutics, Tae-Ho Hwang, Chief Technology Officer, Bionoxx, Xian Zeng, Chief Executive Officer, Byterna Therapeutics, Tina Albertson, Chief Medical Officer, Caribou Biosciences, Jihwan Song, Professor, Founder and Chief Technology Officer, CHA University and iPS Bio, Jeonghoon Han, Chief Executive Officer, Cunnovative, DongHyuk Jeon, Director of Production Center, Curocell, Jiyeon Son, Team Leader, GC Biopharma, Aida Rouzmehr, Material Science Product Lead, Genentech, Ting-Wan Lin, Director of Business Development and Project Manager, GenomeFrontier Therapeutics, Bryan Choi, Professor, INHA University, Mihue Jang, Principal Research Scientist, Korea Institute of Science and Technology, Heesoon Chang, Chief Executive Officer, KW-Bio, Minsung Choy, Director of Regulatory Affairs, Cell Therapy, Legend Biotech, Juhi Verma, Manager, Micro CRISPR, Seungryul Han, Head of R and D (Director), Rznomics, Gi-Hoon Nam, Chief Executive Officer, Shiftbio, Cheng-Yi Jerry Kuo, Vice General Manager, UWELL BioPharma, Je-Jung Lee, Chief Executive Officer, Vaxcell Bio, Bo Ying, Chief Executive Officer, Abogen Bioscience, Kee-Jong Hong, Professor, Gachon University School of Medicine, Takeshi Kuboyama, Strategy Head of Research, AceRNA Technologies, Wonil Kim, Chief Scientific Officer, Executive Vice President and Head of Research Institute, Aston Sci, Kunwoo Lee, Chief Executive Officer, BreezeBio, Peter Weinstein, Chief Executive Officer, Circurna, Kosuke Nakamoto, Principal Scientist, Eisai, Sunjong Kwon, Head of R and D Centre, EyeGene, Jaesung Jung, Director - mRNA Research, GCBiopharma, Jaehyun Choi, Chief Executive Officer, Genexine, Dal-Hee Min, Chief Technology Officer and Professor, Lemonex Bio and Seoul National University, Seihwan Jeong, Project Leader - Cancer Immunotherapy, LG Chem, Kug Hwa Lee, Director, MediciBIO, Yasumasa Ohta, mRNA Technology Leader, Meiji Seika Pharma, Chi-Kang Tseng, Associate Professor, National Taiwan University, Pieter Swanepoel, Director, Technical and Commercial, RNA Australia, Kyung Hyun Lee, Chief Researcher, Rznomics, Saswata Karmakar, Director of Chemistry, mRNA Centre of Excellence, Sanofi, Hyung-Jun Im, Associate Professor and Chief Scientific Officer, Seoul National University and Portal, Dan Peer, Professor, Tel Aviv University, Hoon Sang Lee, Chief Strategy Officer, The RIGHT Foundation, Jeonghwan Kim, Assistant Professor, Yeungnam University

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development

Date and Time: 10th November 2026 at 8:30 am to 12th November 2026 at 3:15 pm